BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

157 related articles for article (PubMed ID: 37608029)

  • 41. Standardized uptake value on FDG-PET as a marker for disease activity in patients with non-Hodgkin's lymphoma: comparison with serum soluble interleukin-2 receptor values.
    Tatsumi M; Sugahara H; Higuchi I; Fukunaga H; Nakamura H; Kanakura Y; Hatazawa J
    Int J Clin Oncol; 2009 Apr; 14(2):150-8. PubMed ID: 19390947
    [TBL] [Abstract][Full Text] [Related]  

  • 42. Positron emission tomography-adapted therapy in low-risk diffuse large B-cell lymphoma: results of a randomized, phase III, non-inferiority trial.
    Shi Q; He Y; Yi HM; Mu RJ; Jiang XF; Fu D; Dong L; Qin W; Xu PP; Cheng S; Song Q; Chen SJ; Wang L; Zhao WL
    Cancer Commun (Lond); 2023 Aug; 43(8):896-908. PubMed ID: 37403255
    [TBL] [Abstract][Full Text] [Related]  

  • 43. Soluble interleukin-2 receptor, soluble CD8 and soluble intercellular adhesion molecule-1 levels in hematologic malignancies.
    Srivastava MD; Srivastava A; Srivastava BI
    Leuk Lymphoma; 1994 Jan; 12(3-4):241-51. PubMed ID: 7909467
    [TBL] [Abstract][Full Text] [Related]  

  • 44. Serum soluble interleukin-2 receptor level as a prognostic indicator in gastric cancer.
    Nakata B; Chung KH; Kato Y; Yamashita Y; Inui A; Arimoto Y; Maeda K; Onoda N; Sawada T; Sowa M
    Br J Cancer; 1998 Jun; 77(11):1820-4. PubMed ID: 9667652
    [TBL] [Abstract][Full Text] [Related]  

  • 45. The role of tumor-associated macrophages on serum soluble IL-2R levels in B-cell lymphomas.
    Sakai A; Yoshida N
    J Clin Exp Hematop; 2014; 54(1):49-57. PubMed ID: 24942946
    [TBL] [Abstract][Full Text] [Related]  

  • 46. Serum levels of soluble interleukin-2 receptor in Hodgkin disease. Relationship with clinical stage, tumor burden, and treatment outcome.
    Ambrosetti A; Nadali G; Vinante F; Carlini S; Veneri D; Todeschini G; Morosato L; de Sabata D; Chilosi M; Maggi E
    Cancer; 1993 Jul; 72(1):201-6. PubMed ID: 8508408
    [TBL] [Abstract][Full Text] [Related]  

  • 47. Soluble interleukin-2 receptor as a clinical parameter for nasopharyngeal carcinoma.
    Hsu MM; Chen YJ; Chang YL; Ko JY; Sheen TS
    Asian Pac J Allergy Immunol; 1995 Jun; 13(1):1-4. PubMed ID: 7488337
    [TBL] [Abstract][Full Text] [Related]  

  • 48. [Aidi Injection-Asisted R-CHOP Chemotherapy for the Treatment of Diffuse Large B-Cell Lymphoma].
    Lu GQ; Zhou XH; Chen H; Tan JP
    Zhongguo Shi Yan Xue Ye Xue Za Zhi; 2016 Jun; 24(3):733-7. PubMed ID: 27342500
    [TBL] [Abstract][Full Text] [Related]  

  • 49. Measurement of the concentration of serum soluble interleukin-2 receptor alpha chain in dogs with lymphoma.
    Mizutani N; Goto-Koshino Y; Kurata K; Fujiwara-Igarashi A; Sakaguchi M; Asada M; Ohno K; Tsujimoto H
    Vet Immunol Immunopathol; 2020 Jul; 225():110054. PubMed ID: 32434088
    [TBL] [Abstract][Full Text] [Related]  

  • 50. Low serum interleukin-2 receptor levels correlate with a good prognosis in patients with Hodgkin's lymphoma.
    Gause A; Roschansky V; Tschiersch A; Smith K; Hasenclever D; Schmits R; Diehl V; Pfreundschuh M
    Ann Oncol; 1991 Feb; 2 Suppl 2():43-7. PubMed ID: 2049320
    [TBL] [Abstract][Full Text] [Related]  

  • 51. Soluble interleukin-2 receptor levels in cerebrospinal fluid of patients with acute lymphocytic leukemia or with non-Hodgkin's lymphoma.
    Chang CS; Liu HW; Lin SF; Chen TP
    Zhonghua Min Guo Wei Sheng Wu Ji Mian Yi Xue Za Zhi; 1989 May; 22(2):132-7. PubMed ID: 2605973
    [TBL] [Abstract][Full Text] [Related]  

  • 52. Cost-effectiveness analysis of the addition of rituximab to CHOP in young patients with good-prognosis diffuse large-B-cell lymphoma.
    Ferrara F; Ravasio R
    Clin Drug Investig; 2008; 28(1):55-65. PubMed ID: 18081361
    [TBL] [Abstract][Full Text] [Related]  

  • 53. [Comparison the efficacy and prognosis of different first-line treatment for elderly diffuse large B-cell lymphoma].
    Liu P; Jiang SY; He XH; Qin Y; Gui L; Zhou SY; Yang JL; Yang S; Wen TY; Shi YK
    Zhonghua Zhong Liu Za Zhi; 2020 Mar; 42(3):234-241. PubMed ID: 32252203
    [No Abstract]   [Full Text] [Related]  

  • 54. Extranodal site of diffuse large B-cell lymphoma and the risk of R-CHOP chemotherapy resistance and early relapse.
    Ting CY; Gan GG; Bee-Lan Ong D; Tan SY; Bee PC
    Int J Clin Pract; 2020 Oct; 74(10):e13594. PubMed ID: 32583545
    [TBL] [Abstract][Full Text] [Related]  

  • 55. [Clinical features and outcomes of newly diagnosed follicular lymphoma concurrent with diffuse large B-cell lymphoma component].
    Lin ZJ; Zha J; Yi SH; Li ZF; Ping LY; He XH; Yu HF; Zheng Z; Xu W; Chen FL; Xie Y; Chen BY; Zhang HL; Wang L; Ding KY; Li WY; Yang HY; Zhao WL; Qiu LG; Li ZM; Song YQ; Xu B
    Zhonghua Xue Ye Xue Za Zhi; 2022 Jun; 43(6):456-462. PubMed ID: 35968587
    [No Abstract]   [Full Text] [Related]  

  • 56. [Diagnostic and prognostic significance of serum soluble interleukin 2 receptor in children with malignancies].
    Bień E; Balcerska A; Ciesielski D
    Wiad Lek; 2006; 59(1-2):10-5. PubMed ID: 16646285
    [TBL] [Abstract][Full Text] [Related]  

  • 57. Impact of serum levels of IL-18 and soluble IL-2 receptor on the clinical outcome of patients with diffuse large B-cell lymphoma treated with R-CHOP regimen.
    Khaled HM; Abdelhamid TM; Abu-Taleb FM; El-Hifnawi NM; Waley AB
    Future Sci OA; 2019 Aug; 5(9):FSO414. PubMed ID: 31608153
    [TBL] [Abstract][Full Text] [Related]  

  • 58. [Relation between the expression of sIL-2R and the relapse in patients with acute lymphoblastic leukemia].
    Liu J; Wu DS; Zhang S; Yan CH; Zhou Y; Zhang YD; Qi ZH
    Beijing Da Xue Xue Bao Yi Xue Ban; 2005 Jun; 37(3):249-51. PubMed ID: 15968312
    [TBL] [Abstract][Full Text] [Related]  

  • 59. Development of a Prognostic Scoring System using MYC Expression and Soluble Interleukin Receptor -2 level for Diffuse Large B-cell Lymphoma.
    Suzuki S; Kuwamoto S; Kawamura K; Matsushita M; Motokura T; Hosoda Y; Maegaki M; Hosoda R; Hara K; Umekita Y; Fukuda T
    Yonago Acta Med; 2023 Feb; 66(1):56-66. PubMed ID: 36820285
    [TBL] [Abstract][Full Text] [Related]  

  • 60. Use of serum soluble interleukin-2 receptor levels to monitor the progression of cutaneous T-cell lymphoma.
    Vonderheid EC; Zhang Q; Lessin SR; Polansky M; Abrams JT; Bigler RD; Wasik MA
    J Am Acad Dermatol; 1998 Feb; 38(2 Pt 1):207-20. PubMed ID: 9486676
    [TBL] [Abstract][Full Text] [Related]  

    [Previous]   [Next]    [New Search]
    of 8.